~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ ~ Funding to Support the Potential Commercialization of PEDMARKTM to Reduce the […]
Read More… from Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor
Research Triangle Park, NC — (Marketwired) –June 14, 2022 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 20, 2022 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders […]
Research Triangle Park, NC, May 23, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor […]
Read More… from FENNEC PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 If Approved by the FDA, PEDMARK™ Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children Company Has Approximately $18.3 Million in Cash and $5 Million of Funded Debt Research Triangle Park, NC, May 12, […]
~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ Research Triangle Park, NC, April 27, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug Application (NDA) for PEDMARKTM (a unique formulation […]
Research Triangle Park, NC, March 25, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the Company will be participating in the 2022 Maxim Group Virtual Growth Conference, taking place March […]
Read More… from FENNEC PHARMACEUTICALS TO PARTICIPATE IN THE 2022 MAXIM VIRTUAL GROWTH CONFERENCE
Research Triangle Park, NC, March 24, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients one month to <18 years of […]
~ Resubmission of NDA for PEDMARKTM Targeted for the First Quarter of 2022 ~ ~ Company has Approximately $21.1 Million in Cash and $5 Million of Funded Debt ~ Research Triangle Park, NC, February 28, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for […]
Research Triangle Park, NC, Jan. 31, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that Shubh Goel, the Company’s chief commercial officer, has tendered her resignation and will depart Fennec in […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE
RESEARCH TRIANGLE PARK, N.C., November 30, 2021 – Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) on November 29, 2021 from the U.S. Food and Drug Administration (FDA), after the PDUFA target action date of November 27, 2021, regarding its New Drug Application (NDA) for PEDMARKTM (a unique formulation […]